Supplementary Figure S3 from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma

Figure S3: (A) Number of mice bearing intracranial allografts of CT2A and xenografts of U251 cells, nontreated or treated with different doses of EdU or thymidine, showing different mortality observations. Mice bearing intracranial allografts of CT2A and xenografts of U251 cells showed body weight loss (BW) as the main mortality observation, followed by crowning (CR),brain seizure (BS), moribund (MO, unknown cause, related symptoms: e.g. Bulging Eyes (BE)) and edema/distended abdomen (E/DA). (B-C) Histogram of mice bearing intracranial allografts of CT2A and xenografts of U251 cells, nontreated or treated with different doses of EdU or thymidine, showing onset of different mortality observations over the course of the study.